Abstract
Background The characteristics of the hemorrhagic location of spontaneous intracerebral hemorrhage (sICH) is pivotal for both identifying its etiology and prognosis. While empirical conclusions have been obtained in clinical practice, a comprehensive and quantitative modeling approach has yet to be thoroughly explored.
Methods We employed lesion-symptom mapping to extract the location features of sICH. We registered patients’ non-contrast computed tomography image and hematoma masks with standard human brain templates to identify specific affected brain regions. Then, we generated hemorrhage probabilistic maps of different etiologies and prognoses. By integrating radiomics and clinical features into multiple logistic regression models, we developed and validated optimal etiological and prognostic models across three centers, comprising 1162 sICH patients.
Results Hematomas of different etiology have unique spatial distributions. Location features robustly categorized the etiology sICH (mean area under the curve (AUC) = 0.825) across different datasets), yielding clear add on value in models (fusion model mean AUC = 0.915) compared to clinical features (mean AUC = 0.828). In the prognostic analysis, patients with more extensive hematoma had a worse prognosis, the location (mean AUC = 0.762) and radiomic features (mean AUC = 0.837) also providing reliable add on value effects (fusion model mean AUC = 0.873) compared to clinical features alone (mean AUC = 0.771).
Interpretation Our results show that location features were more intrinsically robust, generalizable relative, strong interpretability to the complex modeling of radiomics, our approach demonstrated a novel interpretable, streamlined, comprehensive etiologic classification and prognostic prediction framework for sICH.
Competing Interest Statement
Conflict of interest Weixiong Tan, Zhen Zhou, Ping Gong and Xingzhi Chen are employees of Deepwise Inc. The remaining authors have no conflicts of interest
Funding Statement
This study received funding from National Natural Scientific Foundation of China (Grant Nos. 82271983 to X.C., 82127806 to G.L., 81790653 to G.L., and 81701680 to Q.Z.), National Key R&D Program of China (Grant Nos. 2020AAA0109505 to G.L., 2018YFA0701703 to Zhiqiang Zhang).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the ethics Committee of Jinling Hospital, the ethics Committee of Yijishan Hospital and the ethics Committee of Nanjing First Hospital. Informed consents from participating patients were exempted because of the retrospective nature of this study
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding author on reasonable request